ADVERTISEMENT
Analysts Bet On Drugmakers With Domestic Focus As U.S. Price Erosion Escalates
Price erosion has increased again and now impacts the newer portfolio of products as well.
03 Aug 2021, 12:14 PM IST
Analysts and healthcare researchers advised investors to opt for drugmakers with higher exposure to Indian markets than the U.S. as pricing pressure aggravated in the biggest contributor to sales for most pharma companies.Dr. Reddy’s Laboratories Ltd.’s North America generics revenue declined 1% sequentially to $235 million (about Rs 1,747.91 crore).Alembic Pharmaceuticals Ltd.’s U.S. operations revenue dropped 38% quarter-on-quarter...
I’m already a Subscriber Sign In
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Full Access to
NDTV Profit App
Exclusives
Premium Stories
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Minimal Ad
Experience
Members-Only
Rewards
Still Not convinced ? Know More
Get live Stock market updates, Business news, Today’s latest news, Trending stories, and Videos on NDTV Profit.
ADVERTISEMENT